Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
Revenue of Yuhan Corporation (000100.KS)
Revenue in 2023 (TTM): $1.35 B
According to Yuhan Corporation's latest financial reports the company's current revenue (TTM) is $1.35 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Yuhan Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.35 B | $431.86 M | $73.46 M | $55.41 M | $98.64 M |
| 2022 | $1.29 B | $375.59 M | $108.34 M | $68.8 M | $68.96 M |
| 2021 | $1.22 B | $380.27 M | $139.67 M | $91.37 M | $74.35 M |
| 2020 | $1.17 B | $404.74 M | $139.18 M | $173.87 M | $139.71 M |
| 2019 | $1.07 B | $312.28 M | $89.11 M | $39.81 M | $29 M |
| 2018 | $1.1 B | $299.92 M | $110.28 M | $64.79 M | $41.66 M |
| 2017 | $1.06 B | $307.77 M | $149.72 M | $105.04 M | $79.03 M |
| 2016 | $957.31 M | $282.27 M | $181.71 M | $148.51 M | $116.87 M |
| 2015 | $818.1 M | $246.92 M | $148.81 M | $122.02 M | $91.36 M |
| 2014 | $737.47 M | $228.63 M | $118.04 M | $84.15 M | $65.92 M |
| 2013 | $683.93 M | $212.93 M | $104.59 M | $77.64 M | $62.67 M |
| 2012 | $562.77 M | $177.99 M | $88.18 M | $77.58 M | $58.55 M |
| 2011 | $492.3 M | $183.4 M | $91.8 M | $77.45 M | $68.29 M |
| 2010 | $480.95 M | $199.81 M | $116.57 M | $103.65 M | $92.78 M |
| 2009 | $468.78 M | $209.67 M | $119.79 M | $99.09 M | $88.24 M |
| 2008 | $442.99 M | $211.08 M | $122.05 M | $105.1 M | $91.07 M |
| 2007 | $357.53 M | $176.55 M | $94.46 M | $76 M | $66.73 M |